Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: Results from a randomised, controlled, double-blind trial

Vaccine

Volumn 31, Issue 51, 2013, Pages 6136-6143

  Richardus, Jan Hendrik ^a  

^a Public Health Service of the Rotterdam Region   (Netherlands)

Author keywords

Genital herpes; Herpes simplex virus type 1; Herpes simplex virus type 2; HSV vaccine; Safety

Indexed keywords

3 O DEACYLATED MONOPHOSPHORYL LIPID A; ALUMINUM HYDROXIDE; GLYCOPROTEIN D; HEPATITIS A VACCINE; HERPES SIMPLEX VACCINE; IMMUNOLOGICAL ADJUVANT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACNE; ADOLESCENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; ASTHMA; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GENITAL HERPES; HEADACHE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LIP DISEASE; LIP SWELLING; MALAISE; MENTAL DISEASE; MIGRAINE; NEPHROTIC SYNDROME; NORMAL HUMAN; OUTCOME ASSESSMENT; PAIN; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SCHOOL CHILD; SPONTANEOUS ABORTION; SUICIDAL IDEATION; TACHYCARDIA; URTICARIA; VIRUS INFECTION;

(S)AE; (SERIOUS) ADVERSE EVENT; 95% CI; 95% CONFIDENCE INTERVAL; ACCORDING TO PROTOCOL; ALUM; ALUMINIUM HYDROXIDE; ALUMINIUM HYDROXIDE AND 3-O-DEACYLATED MONOPHOSPHORYL LIPID A ADJUVANT SYSTEM; AS04; ATP; ELISA; ELISA UNITS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EU; GD2; GENITAL HERPES; GEOMETRIC MEAN CONCENTRATION; GLAXOSMITHKLINE; GMC; GSK; HAV; HEPATITIS A VACCINE; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS TYPE 1; HERPES SIMPLEX VIRUS TYPE 2; HERPES SIMPLEX VIRUS TYPE 2 GLYCOPROTEIN D; HSV; HSV VACCINE; HSV-1; HSV-2; IGG; IMMUNOGLOBULIN G; INTERNATIONAL UNITS; IU; MONOPHOSPHORYL LIPID A; MPL; NEW ONSET CHRONIC DISEASES; NOCD; OD; OPTICAL DENSITY; SAFETY; TOTAL VACCINATED COHORT; TVC;

ADOLESCENT; CHILD; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; HUMANS; PLACEBOS; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS;

EID: 84888430169     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.081     Document Type: Article

References (20)

1. Xu F., Sternberg M.R., Kottiri B.J., McQuillan G.M., Lee F.K., Nahmias A.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296(8):964-973.
2. Langenberg A., Benedetti J., Jenkins J., Ashley R., Winter C., Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 1989, 110(11):882-887.
3. Kemble G., Spaete R. Herpes simplex vaccines. Human herpesviruses: biology, therapy, and immunoprophylaxis 2007, Cambridge University Press, Cambridge. A. Arvin, G. Campadelli-Fiume, E. Mocarski, P.S. Moore, B. Roizman, R. Whitley, K. Yamanishi (Eds.).
4. Brown E.L., Gardella C., Malm G., Prober C.G., Forsgren M., Krantz E.M., et al. Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. Acta Obstet Gynecol Scand 2007, 86(5):523-529.
5. Tuite A.R., McCabe C.J., Ku J., Fisman D.N. Projected cost-savings with herpes simplex virus screening in pregnancy: towards a new screening paradigm. Sex Transm Infect 2011, 87(2):141-148.
6. Perez G., Skurnick J.H., Denny T.N., Stephens R., Kennedy C.A., Regivick N., et al. Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis 1998, 3(1):5-11.
7. Chen C.Y., Ballard R.C., Beck-Sague C.M., Dangor Y., Radebe F., Schmid S., et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000, 27(1):21-29.
8. de Jong M.A., de Witte L., Taylor M.E., Geijtenbeek T.B. Herpes simplex virus type 2 enhances HIV-1 susceptibility by affecting Langerhans cell function. J Immunol 2010, 185(3):1633-1641.
9. Ryder N., Jin F., McNulty A.M., Grulich A.E., Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sex Transm Infect 2009, 85(6):416-419.
10. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347(21):1652-1661.
11. Belshe R.B., Leone P.A., Bernstein D.I., Wald A., Levin M.J., Stapleton J.T., et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012, 366(1):34-43.
12. Bernstein D.I., Aoki F.Y., Tyring S.K., Stanberry L.R., St Pierre C., Shafran S.D., et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005, 40(9):1271-1281.
13. Centers for Disease Control Prevention (CDC) Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years - United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010, 59(15):456-459.
14. Sauerbrei A., Schmitt S., Scheper T., Brandstädt A., Saschenbrecker S., Motz M., et al. Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 2006. Euro Surveill 2011, 16(44):1-7.
15. Ashley R., Cent A., Maggs V., Nahmias A., Corey L. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 1991, 115(7):520-526.
16. Schwarz T.F., Huang L.M., Medina D.M., Valencia A., Lin T.Y., Behre U., et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health 2012, 50(2):187-194.
17. Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T., Breuer T., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5(5):332-340.
18. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008, 8(2):235-247.
19. Verstraeten T., Descamps D., David M.P., Zahaf T., Hardt K., Izurieta P., et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008, 26(51):6630-6638.
20. Garcon N., Segal L., Tavares F., Van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 2011, 29(27):4453-4459.